Methods of treating OX40 mediated recall immune responses

Details Methods of treating OX40 mediated recall immune responses Methods of treating OX40 mediated recall immune responses

2007-10-16

2010-10-05

Ouspenski, Ilia (Department: 1644)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Reexamination Certificate

active

07807156

ABSTRACT:
T cell memory can persist in the absence of antigen. However, some memory cells by default are subject to signals accompanying periodic antigen exposure. OX40 is essential to the extent and persistence of Th2 memory when antigen is re-encountered. In an animal model of allergic asthma, inhibiting OX40/OX40L signaling during the secondary response to inhaled antigen suppressed lung inflammation. Inhibiting OX40 at the time of memory cell reactivation reduced the longevity of memory with further inflammation prevented upon tertiary encounter with antigen.

REFERENCES:
patent: 5457035 (1995-10-01), Baum et al.
patent: 5759546 (1998-06-01), Weinberg et al.
patent: 5783665 (1998-07-01), Baum et al.
patent: 6312700 (2001-11-01), Weinberg
patent: 6566082 (2003-05-01), Weinberg et al.
patent: 2002/0054873 (2002-05-01), Weinberg
patent: 2004/0009174 (2004-01-01), Arndt et al.
patent: 2004/0136992 (2004-07-01), Burton et al.
patent: WO 95/21251 (1995-08-01), None
patent: WO 99/42585 (1999-08-01), None
Arestides RS, et al. Costimulatory molecule OX4OL is critical for both Th1 and Th2 responses in allergic inflammation. Eur J Immunol. 2002; 32:2874-80.
Hoshino A, et al. Critical role for OX 40 ligand in the development of pathogenic Th2 cells in a murine model of asthma. Eur J Immunol. 2003; 33:861-9.
Amha Gebre-Hiwot Jember, et al., Development of Allergic Inflammation in a Murine Model of Asthma Is Dependent on the Costimulatory Receptor OX40, J. Exp. Med. 193(3):387-392 (2001).
Huang, Z., et al., Structural Chemistry and Therapeutic Intervention of Protein-Protein Interactions in Immune Response, Human Immunodeficiency Virus Entry, and Apoptosis, Pharmacology and Therapeutics, 2000, 86:201-215.
Imura, Akihiro, et al., The Human OX40/gp34 System Directly Mediates Adhesion of Activated T Cells to Vascular Endothelial Cells, J. Exp. Med., 1996, 183:2185-2195.
Imura, Akihiro, et al., OX40 Expressed on Fresh Leukemic Cels from Adult T-Cell Leukemia Patiens Mediates Cell Adhesion to Vascular Endothelial Cells: Implication fo rhte Possible Involvements of OX40 in Leukemic Cell Infiltration, Blood, 1997, 89:2951-2958.
Basic Facts about Asthma, 2003, at cdc.gov/asthma/faqs.
Evans, Dean E., et al., Engagement of OX40 enhances antigen-specific CD4+T cell mobilization/memory development and humoral immunity: Comparison of αOX-40 with αCTLA-4,J. of Immunology, 2001, 167:6804-6811.
Gramaglia, Irene, et al., Ox-40 Ligand: A potent costimulatory molecule for sustaining primary CD4 T cell responses,J. of Immunology, 1998, 161:6510-6517.
Gramaglia, Irene, et al., The OX40 costimulatory receptor determines the development of CD4 memory by regulating primary clonal expansion,J. of Immunology, 2000, 165:3043-3050.
Henderson, William R., et al., Soluble IL-4 Receptor Inhibits Airway Inflammation Following Allergen Challenge in a Mouse Model of Asthma,J. of Immunology, 2000, 164:1086-1095.
Kjaergaard, Jorgen, et al., Augmentation versus inhibition: Effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor,J. of Immunology, 2001, 167: 6669-6677.
Kobayashi, Tetsuto, et al., An Essential Role of Mast Cells in the Development of Airway Hyperresponsiveness in a Murine Asthma Model,J. of Immunology, 2000, 164:3855-3861.
Maxwell, Joseph R., et al., Danger and OX40 receptor signaling synergize to enhance memory T Cell survival by inhibiting peripheral deletion,J. of Immunology, 2000, 164:107-112.
Mellis, CM, Is asthma prevention possible with dietary manipulation?, Med. J. Aust., 2002, 177:S78-S80.
Owens et al., The genetic engineering of monoclonal antibodies, Journal of Immunological Methods, 1994, 168: 149-165.
Pan, Ping-Ying, OX40 Ligation enhances primary and memory cytoxic T lymphocyte responses in an immunotherapy for hepatic colon metastases,Molecular Therapy, 6(4):528-536 (2002).
Roitt, Ivan M.; Brostoff, Jonathan; and Male, David K.,Immunology, 2nd ed., 1989, pp. 1.1, 2.8, 8.1-8.2, Gower Medical Publishing, 34-42 Cleveland Streeet, London W1P 5Fb, England.
Salek-Ardakani, Shahram, et al., OX40 (CD134) Controls Memory T Helper 2 Cells that Drive Lung Inflammation,J. Exp. Med., 2003, 198(2):315-324.
Weatherill, Amy R., et al., OX40 Ligation enhances cell cycle turnover of Ag-activated CD4 T Cell in Vivo,Cellular Immunology, 209, 63-75 (2001).
Weinberg, Andrew D., et al., Blocking OX-40/OX-40 Ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis,J. of Immunology, 1999, 162: 1818-1826.
Weinberg, Andrew D., Ox40: Targeted imunotherapy-implications for tempering autoimmunity and enhancing vaccines,TRENDS in Immunology, 20(2):102-109 (Feb. 2002).
Yoshioka, T., et al., Contribution of OX40/OX40 Ligand interaction to the pathogenesis of rheumatoid arthritis, Eur. J. Immunol. 30:2815-2823 (2000).

Affiliated with

Also associated with

Rating

Methods of treating OX40 mediated recall immune responses does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of treating OX40 mediated recall immune responses, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating OX40 mediated recall immune responses will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4178430